» Articles » PMID: 40066451

The Role of MA Modification During Macrophage Metabolic Reprogramming in Human Diseases and Animal Models

Overview
Journal Front Immunol
Date 2025 Mar 11
PMID 40066451
Authors
Affiliations
Soon will be listed here.
Abstract

Macrophage metabolic reprogramming refers to the process by which macrophages adjust their physiological pathways to meet survival and functional demands in different immune microenvironments. This involves a range of metabolic pathways, including glycolysis, the tricarboxylic acid cycle, oxidative phosphorylation, fatty acid oxidation, and cholesterol transport. By modulating the expression and activity of key enzymes and molecules within these pathways, macrophages can make the transition between pro- and anti-inflammatory phenotypes, thereby linking metabolic reprogramming to inflammatory responses and the progression of several diseases, such as atherosclerosis, inflammatory bowel disease (IBD), and acute lung injury (ALI). N6-methyladenosine (mA) modification has emerged as a critical regulatory mechanism during macrophage metabolic reprogramming, broadly affecting RNA stability, translation, and degradation. Therapeutic strategies targeting mA modification can regulate the onset of metabolic diseases by influencing macrophage metabolic changes, for instance, small molecule inhibitors of methyltransferase-like 3 (METTL3) can affect glucose metabolism and inhibit IBD. This review systematically explores recent findings on the role and molecular mechanisms of mA modification during macrophage metabolic reprogramming in human diseases and animal models, underscoring its potential as a therapeutic target for metabolic diseases.

References
1.
Li J, Wei L, Hu K, He Y, Gong G, Liu Q . Deciphering mA methylation in monocyte-mediated cardiac fibrosis and monocyte-hitchhiked erythrocyte microvesicle biohybrid therapy. Theranostics. 2024; 14(9):3486-3508. PMC: 11209724. DOI: 10.7150/thno.95664. View

2.
Fitzpatrick S, Tambuwala M, Bruning U, Schaible B, Scholz C, Byrne A . An intact canonical NF-κB pathway is required for inflammatory gene expression in response to hypoxia. J Immunol. 2010; 186(2):1091-6. DOI: 10.4049/jimmunol.1002256. View

3.
Palmieri F . The mitochondrial transporter family (SLC25): physiological and pathological implications. Pflugers Arch. 2003; 447(5):689-709. DOI: 10.1007/s00424-003-1099-7. View

4.
Qi L, Wang Y, Hu H, Li P, Hu H, Li Y . mA methyltransferase METTL3 participated in sympathetic neural remodeling post-MI via the TRAF6/NF-κB pathway and ROS production. J Mol Cell Cardiol. 2022; 170:87-99. DOI: 10.1016/j.yjmcc.2022.06.004. View

5.
Guo M, Yan R, Ji Q, Yao H, Sun M, Duan L . IFN regulatory Factor-1 induced macrophage pyroptosis by modulating m6A modification of circ_0029589 in patients with acute coronary syndrome. Int Immunopharmacol. 2020; 86:106800. DOI: 10.1016/j.intimp.2020.106800. View